Taysha Gene Market Capitalization Over Time
| TSHA Stock | USD 2.40 0.12 4.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Taysha Gene Performance and Taysha Gene Correlation. Taysha |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share 0.042 | Quarterly Revenue Growth (0.62) | Return On Assets (0.27) | Return On Equity (1.15) |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Market Cap Analysis
Compare Taysha Gene Therapies and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Market Capitalization Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EQ | 99.5 M | 99.5 M | 99.5 M | 99.5 M | 99.5 M | 99.5 M | 99.5 M | 99.5 M | 99.5 M | 58.7 M | 108.9 M | 108.6 M | 35.8 M | 25.1 M | 23.9 M |
| DMAC | 7.1 M | 70.5 M | 56.6 M | 42 M | 10.4 M | 10.4 M | 10.4 M | 29 M | 22.5 M | 58.1 M | 159 M | 77.5 M | 41.8 M | 37.6 M | 32.3 M |
| VALN | 99.1 M | 115.7 M | 144.2 M | 163.7 M | 235.3 M | 282.2 M | 230.7 M | 218.9 M | 255.3 M | 235.8 M | 703.4 M | 718.7 M | 718.7 M | 655.8 M | 688.6 M |
| VANI | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 840.5 M | 209.9 M | 77.9 M | 103.4 M | 58.8 M | 87.3 M | 38.5 M | 53.9 M | 32.5 M | 37.4 M | 35.5 M |
| DNLI | 64.5 M | 64.5 M | 64.5 M | 64.5 M | 64.5 M | 64.5 M | 234 M | 234 M | 1.9 B | 1.7 B | 9.1 B | 3.5 B | 3.5 B | 2.9 B | 2.2 B |
| DNTH | 513.6 M | 513.6 M | 513.6 M | 513.6 M | 513.6 M | 513.6 M | 513.6 M | 513.6 M | 104.8 M | 561.1 M | 344.3 M | 243.4 M | 23.7 M | 53.6 M | 50.9 M |
| DOMH | 14.7 M | 3.2 M | 5 M | 27.3 M | 19.2 M | 4.3 M | 3.5 M | 6.8 M | 4.6 M | 3.3 M | 24.4 M | 48.6 M | 13.5 M | 15.6 M | 27.4 M |
| VCEL | 49 M | 70.3 M | 51.9 M | 181.8 M | 181.8 M | 181.8 M | 181.8 M | 181.8 M | 768.7 M | 768.7 M | 1.8 B | 1.8 B | 1.8 B | 1.6 B | 1.7 B |
| VCNX | 63.2 M | 63.2 M | 63.2 M | 63.2 M | 63.2 M | 63.2 M | 63.2 M | 64.9 M | 19 M | 62.5 M | 38.9 M | 27.4 M | 27.4 M | 4.3 M | 4.1 M |
| VCYT | 188.1 M | 188.1 M | 188.1 M | 209 M | 209 M | 186.8 M | 223.1 M | 221.5 M | 465.7 M | 1.3 B | 2.6 B | 2.8 B | 1.7 B | 2 B | 2.1 B |
Taysha Gene Therapies and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Market Cap description
My Equities
My Current Equities and Potential Positions
| Taysha Gene Therapies | TSHA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.4
Check out Taysha Gene Performance and Taysha Gene Correlation. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Taysha Gene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.